1. Home
  2. FORTY vs BEAM Comparison

FORTY vs BEAM Comparison

Compare FORTY & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FORTY

Formula Systems (1985) Ltd.

HOLD

Current Price

$174.69

Market Cap

2.6B

Sector

Technology

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$26.72

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FORTY
BEAM
Founded
1985
2017
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.3B
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
FORTY
BEAM
Price
$174.69
$26.72
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$48.09
AVG Volume (30 Days)
602.0
2.0M
Earning Date
11-20-2025
11-04-2025
Dividend Yield
0.99%
N/A
EPS Growth
N/A
N/A
EPS
4.53
N/A
Revenue
$3,016,039,000.00
$55,701,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$26.52
P/E Ratio
$37.72
N/A
Revenue Growth
11.45
N/A
52 Week Low
$80.15
$13.53
52 Week High
$176.50
$35.25

Technical Indicators

Market Signals
Indicator
FORTY
BEAM
Relative Strength Index (RSI) 70.07 56.13
Support Level $149.75 $25.86
Resistance Level $169.03 $28.28
Average True Range (ATR) 2.04 1.63
MACD 2.13 0.25
Stochastic Oscillator 99.19 58.35

Price Performance

Historical Comparison
FORTY
BEAM

About FORTY Formula Systems (1985) Ltd.

Formula Systems (1985) Ltd is a holding company that, through its subsidiaries, provides information technology services. The company organizes itself into operating segments: The Matrix segment, which generates the majority of revenue, provides software development and existing software expansion services. The Sapiens segment provides software development services for the insurance industry. The Magic Software segment provides vendor management systems and workforce management services, which include accounting and finance, human resources, Michpal, ZAP Group, and Others. The majority of the company's revenue comes from Israel.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: